Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Vam3 in preparing medicine for treating chronic obstructive disease of lung

A technology for chronic obstructive pulmonary diseases, applied in drug combinations, respiratory diseases, pharmaceutical formulations, etc.

Inactive Publication Date: 2007-10-24
INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
View PDF1 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The anti-COPD effect of Vam3 has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Vam3 in preparing medicine for treating chronic obstructive disease of lung
  • Application of Vam3 in preparing medicine for treating chronic obstructive disease of lung

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0009] Example 1 Inhibitory effect of Vam3 on the production of inflammatory mediators in bronchoalveolar lavage fluid (BALF) of COPD mice

[0010] (1) Inhibitory effect of Vam3 on TNFα production in BALF of COPD mice

[0011] The proinflammatory cytokine TNFα is an initiating factor in the pathogenesis of COPD. The level of TNFα in COPD patients is higher than that of normal people, and the cultured bronchial epithelial cells can secrete TNFα in contact with cigarette smoke. TNFα can promote neutrophil degranulation, induce mucosal cell proliferation and hypersecretion, increase the production of IL-8 in epithelial cells, increase the production of matrix metalloproteinases in macrophages, and promote airway hyperresponsiveness. The purpose of this experiment is to investigate the effect of Vam3 on the production of TNFα in the BALF of COPD mice. The results are shown in Table 1.

[0012] compound

dosage

(mg / kg)

Content of TNFα in BALF of COPD mic...

Embodiment 2

[0030] Example 2 The inhibitory effect of Vam3 on the recruitment of inflammatory cells in the BALF of COPD mice

[0031] (1) The inhibitory effect of Vam3 on the recruitment of total inflammatory cells in the BALF of COPD mice

[0032] COPD is characterized by chronic inflammation throughout the airways, lung parenchyma, and pulmonary vessels, manifested by an increase in neutrophils, T lymphocytes, and macrophages in the lungs. Activated inflammatory cells release a range of inflammatory mediators, including LTB 4 , IL-8, TNFa, and other mediators that can damage lung structures or maintain neutrophil inflammation. The purpose of this experiment is to investigate the effect of Vam3 on the recruitment of total inflammatory cells in the BALF of COPD mice. The results are shown in Table 5.

[0033] compound

dosage

(mg / kg)

Total count of inflammatory cells in BALF of COPD mice

(10 5 cell / ml)

Vam3

Terbutaline

Model compariso...

Embodiment 3

[0046] Example 3. Reversal effect of Vam3 on lung pathological changes in COPD mice

[0047] The pathological observation of the mouse lungs showed that the alveolar wall in the model group was widened, the epithelial cells of the alveolar wall were swollen, rounded, and partly shed, macrophages could be seen in the alveolar cavity, focal inflammatory cell infiltration around the small bronchi and bronchioles, lung tissue The marginal alveolar spaces are dilated. In the Vam3 group, the alveolar wall epithelial cells were swollen, and a small amount of macrophages and granulocytes were infiltrated in the alveolar space, but no lymphocyte infiltration was seen, and no hemorrhage was found in the lung tissue of the mice.

[0048] Conclusion: Vam3 administered by intragastric administration at doses of 50, 100, and 200 mg / kg has a certain therapeutic effect on chronic obstructive pulmonary congestion and inflammatory cell infiltration in mice induced by cigarettes.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses the novel use of Vam 3 (Amurensin H) with a general formula (I) in preparing medicament for preventing and / or treating chronic obstructive pulmonary disease.

Description

technical field [0001] The present invention relates to the new medical application of Vam3 (Amurensin H) represented by the formula (I). Background technique [0002] Chronic obstructive pulmonary disease (chronic obstructive pulmonary disease, COPD) is a common chronic disease worldwide, currently ranking fourth in the global cause of death, according to the World Health Organization forecast, by 2020, COPD will be in the global disease Ranked fifth and third among causes of death. [0003] COPD is a disease characterized by not fully reversible airflow limitation associated with an abnormal inflammatory response of the lungs to noxious gases or noxious particles, with chronic inflammation throughout the airways, lung parenchyma, and pulmonary vessels. The cells involved in COPD include inflammatory cells such as neutrophils, T lymphocytes, and macrophages. When the cells are activated, they release various inflammatory mediators, such as leukotriene B 4 (LTB 4 ), inter...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/343A61P11/00
Inventor 李怡棠程桂芳林茂姚春所黄开胜刘柏合白金叶李娜
Owner INST OF MATERIA MEDICA CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com